NCT00250445CompletedPhase 3
A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Organon and Co
- Enrollment
- 23,498
- Primary Endpoint
- Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences based on combined data from this trial and MK0663 Protocols 061 & 072 (GI Tolerability in OA Patients and GI Tolerability Study in RA Patients ), respectively.
Study Overview
Brief Summary
The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines. The study will be conducted in patients with either rheumatoid or osteo-arthritis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient has a clinical diagnosis of either Osteoarthritis or Rheumatoid Arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or COX-2 inhibitor therapy for at least 1.5 years
Exclusion Criteria
- •Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation.
- •Concomitant therapy of warfarin, heparin, high-dose aspirin (>100 mg/day).
- •Impaired kidney function, clinical gastrointestinal malabsorption, congestive heart failure with symptoms that occur at rest, unstable angina, uncontrolled high blood pressure, active hepatitis/hepatic disease
Outcomes
Primary Outcomes
Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences based on combined data from this trial and MK0663 Protocols 061 & 072 (GI Tolerability in OA Patients and GI Tolerability Study in RA Patients ), respectively.
Secondary Outcomes
- Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences from this trial alone. Gastrointestinal tolerability based on the percentage of patients that discontinue for clinical or laboratory gastrointestinal adverse experiences.
Investigators
Similar Trials
Completed
Phase 3
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)Acute Coronary SyndromePercutaneous Coronary InterventionNCT01294462AstraZeneca801
Unknown
Phase 1
Ph1 Lobeline Interaction Study - 1Methamphetamine DependenceNCT00439504National Institute on Drug Abuse (NIDA)10
Completed
Phase 3
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusDiabetes Mellitus Type 2NCT01042769Hoffmann-La Roche7,226
Withdrawn
Phase 4
Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes PatientsType 2 DiabetesNCT00399204Post Graduate Institute of Medical Education and Research, Chandigarh
Completed
Not Applicable
Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic TreatmentsDiabetes Mellitus, Type 2NCT01086280AstraZeneca113,505